Patent ductus arteriosus management and the drift towards therapeutic nihilism - What is the evidence?

The published literature on patent ductus arteriosus (PDA) management is challenging to interpret due to poorly designed trials with high rates of open label treatments, homogenisation of patients with varying physiological subtypes, poor treatment efficacy, and spontaneous closure in more mature infants. The perceived lack of clinical benefit has led to a drift away from medical and surgical treatment of all infants with a PDA. This therapeutic nihilism as a default response to PDA management fails to recognise the physiological relevance of a left-to-right shunt with early haemodynamic instability after birth and subsequent pulmonary volume overload with prolonged exposure. Clinicians need to know if therapeutic nihilism is safe. This review will provide an overview of the available data on the efficacy of known PDA treatments, conservative management and supportive care measures that are currently applied.

Automated summary

The literature on PDA management is challenging due to poorly designed trials with high rates of open label treatments. Therapeutic nihilism has led to a drift away from medical and surgical treatment, failing to recognize the physiological relevance of a left-to-right shunt. The safety of therapeutic nihilism needs to be further evaluated.